Data from preclinical studies conducted to examine the activities of the novel estrogen receptor beta (ERbeta) agonist EGX-358, previously under study for the treatment of hot flushes at Estrigenix Therapeutics, for the potential treatment of Alzheimer's disease (AD) were presented at the recent Alzheimer's Association International Conference.

At the Alzheimer's Association International Conference, Dong-A ST scientists described preclinical research on a new tau-targeted agent, DA-7503.

Investigators from Emory University and affiliated organizations presented preclinical data for the IAP inhibitor AZD-5582 (AstraZeneca), which has previously demonstrated the ability to systemically reverse latency in animal models of HIV.

During a presentation at the Alzheimer's Association International Conference 2022, researchers from the Genetic Frontotemporal Dementia (FTD) Initiative consortium presented data from a study following nearly 1,300 patients with FTD caused by a genetic mutation, their presymptomatic family members who have the inherited mutation and unaffected family members to serve as controls. Researchers have used data from the study, which has been enrolling patients for over 10 years, to develop biomarkers that can be used to assess progression of FTD in interventional clinical trials.

Researchers from Cantargia and Johns Hopkins University School of Medicine presented data from a preclinical study evaluating an IL-1 receptor accessory protein (IL-1RAP)-blocking antibody, CAN-10, in a model of acute coxsackievirus B3 (CVB3) myocarditis.

Keeping innovation growing at a fast clip while retaining new global supply chain capacity built up during the pandemic were the main topics of discussion at the Bio Asia-Taiwan conference July 27 in Taipei. With the theme of the conference, “Connecting the Asia Value Chain,” Taiwan Vice President Ching-Te Lai said the pandemic has demonstrated Taiwan’s resilience as well as the strength of the global biopharma industry.